| 1. |
|
|
| 2. |
|
|
| 3. |
- Magnusson, Börje, et al.
(författare)
-
Drömmen om stormakten : Erik Dahlberghs Sverige
- 2015
-
Bok (övrigt vetenskapligt/konstnärligt)abstract
- Ingen har betytt så mycket för bilden av den svenska stormakten, dess städer och slott, som Erik Dahlbergh, Han påbörjade 1661 det svindlande projektet att avbilda sevärdheter från alla delar av Sverige. Den ambitiösa satsningen resulterade i verket Suecia antiqua et hodierna, "Det forna och nuvarande Sverige", med en stor mängd planscher som återutgivits under århundraden. Länge ansågs verket framställa Sverige som mer storslaget än det faktiskt var. Men hur är det egentligen med överdrifterna? Och vilka är människorna som rör sig i slottsmiljöerna? Vad kan vi från bilderna utläsa om livet i den svenska stormakten? Konsthistorikerna Börje Magnusson och historikern Jonas Nordin går på en fascinerande upptäcktsfärd i 1600-talets Sverige.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Moraes, Luiza, et al.
(författare)
-
Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms.
- 2020
-
Ingår i: Inflammatory bowel diseases. - : Oxford University Press (OUP). - 1536-4844 .- 1078-0998. ; 26:6, s. 874-884
-
Tidskriftsartikel (refereegranskat)abstract
- Inflammatory mechanisms of ulcerative colitis (UC) and irritable bowel syndrome (IBS) may overlap or are part of different spectrums. However, potential links between inflammation and IBS-like symptoms in these patient groups are still unclear. The aim of this study was to determine if the systemic inflammatory protein (SIP) profiles differ between UC patients, with presence of inflammation or in remission with or without IBS-like symptoms, and IBS patients.Serum from patients with active UC (UCA), UC patients in remission with or without IBS-like symptoms (UCR+IBS, UCR-IBS), IBS patients (IBS), and healthy subjects (HS) was analyzed using the ProSeek Multiplex Inflammation kit, which detects 92 proteins.The exploratory cohort consisted of 166 subjects (UCA, n = 40; UCR-IBS, n = 45; UCR+IBS, n = 20; IBS, n = 40; HS, n = 21). Systemic inflammatory protein profiles separated UC from non-UC (HS and IBS) patients in multivariate analysis, revealing caspase 8, axin 1, sulfotransferase 1A1, and tumor necrosis factor superfamily member 14 as the variables most important to clustering. Although minor differences were detected between UCR+IBS and UCR-IBS, SIP profiles discriminated UCA from UCR, and interleukin (IL) 17C, IL17A, chemokine ligand 9, and transforming growth factor-α characterized active inflammation. SIP profiles weakly discriminated HS from IBS, although fibroblast growth factor 21 and IL6 serum levels were higher in IBS. Results were confirmed in a validation cohort (UCA, n = 15; UCR+IBS, n = 9; IBS, n = 14).SIP profiles distinguish UC patients from IBS patients, irrespective of inflammation or IBS-like symptoms, suggesting that inflammatory mechanisms of the diseases are part of different spectrums.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Wadenvik, Hans, 1955, et al.
(författare)
-
The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia.
- 1991
-
Ingår i: Blood. - 0006-4971. ; 77:10, s. 2103-8
-
Tidskriftsartikel (refereegranskat)abstract
- In 10 patients with previously untreated essential thrombocythemia (ET), by using 111In-labeled platelets and megakaryocyte morphometry, the relation between platelet production rate and bone marrow megakaryocytes was evaluated before and during alpha-2b-interferon (IFN) therapy. A highly significant decrease in platelet count occurred during IFN therapy; the platelet counts, at baseline and after 2 and 6 months of IFN therapy, were 1,102 +/- 345 x 10(9)/L, 524 +/- 169 x 10(9)/L (P less than .0001), and 476 +/- 139 x 10(9)/L (P less than .0001), respectively. The decrement in platelet count was mainly a result of diminished platelet production rate, which at baseline and after 2 and 6 months of IFN therapy was 89 +/- 30 x 10(10) platelets/d, 53 +/- 18 x 10(10) platelets/d (P = .0033), and 45 +/- 20 x 10(10) platelets/d (P less than .0001), respectively. Also, a slight shortening of platelet mean life-span (MLS) was observed in response to IFN treatment; platelet MLS was 7.96 +/- 0.69 days at baseline and 6.68 +/- 1.30 days (P = .012) after 6 months of IFN therapy. IFN induced a significant decrease in bone marrow megakaryocyte volume; both megakaryocyte nuclear and cytoplasmatic volumes were affected. The mean megakaryocyte volume was 372 +/- 126 x 10(2) pL/microL at baseline and 278 +/- 147 x 10(2) pL/microL (P = .049) after 6 months of IFN therapy. However, the number of megakaryocytes did not show any significant change in response to IFN. It is concluded that alpha-IFN reduces platelet production rate and the peripheral platelet count in ET mainly through an anti-proliferative action on the megakaryocytes and to a considerably lesser degree by a shortening of platelet MLS.
|
|
